Terms of Use

The Oncology Failure Atlas is a public-data research intelligence platform. It is intended to help users explore publicly reported oncology trial discontinuation patterns.

The platform does not provide clinical, medical, regulatory, financial, investment, or legal advice.

The platform does not determine the definitive cause of any trial's discontinuation. It classifies publicly reported discontinuation patterns using source-linked evidence and confidence-tiered audit logic.

RecurSignal™ is a historical recurrence signal. It is not a prediction, probability, forecast, or risk score.

The Phase 1 dataset includes terminated and withdrawn oncology trials only. It does not include the full denominator of all attempted, completed, or successful oncology trials and does not calculate a true failure rate.

Public source coverage may be incomplete because of metadata gaps, missing NCT IDs in publications, investigational compound naming, drug-name normalization limitations, and source-update timing.

Users are responsible for independently verifying any source evidence before making research, commercial, clinical, regulatory, or investment decisions.

MDIP™ and RecurSignal™ are proprietary frameworks developed by Pharma Innovation Research by Sebastian Azar.